MARKET

SABSW

SABSW

SAB BIOTHERAPEUTICS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.250
-0.140
-10.07%
Closed 16:00 01/14 EST
OPEN
1.370
PREV CLOSE
1.390
HIGH
1.430
LOW
1.180
VOLUME
137.42K
TURNOVER
--
52 WEEK HIGH
3.320
52 WEEK LOW
0.4702
MARKET CAP
--
P/E (TTM)
-2083.3333
1D
5D
1M
3M
1Y
5Y
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by DiversitAb™ platform in past two months Positive clinical resul...
GlobeNewswire · 12/01/2021 12:00
BRIEF-Sab Biotherapeutics Reports Q3 Financial Results
reuters.com · 11/22/2021 12:05
Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics
Big Cypress Acquisition Corp. (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that its stockholders have approved the proposed business combination (the "Bus...
PR Newswire · 10/21/2021 11:00
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
SIOUX FALLS, S.D., October 06, 2021--SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
Business Wire · 10/06/2021 11:00
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
SIOUX FALLS, S.D., October 04, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human d...
Business Wire · 10/04/2021 11:00
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
SIOUX FALLS, S.D., September 28, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human...
Business Wire · 09/28/2021 11:00
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
SIOUX FALLS, S.D., September 24, 2021--SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human...
Business Wire · 09/24/2021 11:00
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders (the "Special Meeting") to, ...
PR Newswire · 09/23/2021 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SABSW. Analyze the recent business situations of SAB BIOTHERAPEUTICS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
0.090.330.570.81
Q1 2021
Q2 2021
Q3 2021
Q4 2021
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About SABSW
SAb Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.

Webull offers kinds of SAB Biotherapeutics Inc stock information, including NASDAQ:SABSW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABSW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SABSW stock methods without spending real money on the virtual paper trading platform.